Bortezomib: A Review of its Use in Patients with Multiple Myeloma
Bortezomib: A Review of its Use in Patients with Multiple Myeloma
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Summary
Bortezomib (VELCADE®) is a proteasome inhibitor that not only targets the myeloma cell, but also acts in the bone marrow micro-environment, inhibiting the binding of myeloma cells to bone marrow stromal cells, as well as demonstrating anabolic effects on bone.
Intravenous bortezomib, with or without dexamethasone, is effective and wel...
Alternative Titles
Full title
Bortezomib: A Review of its Use in Patients with Multiple Myeloma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_228087775
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_228087775
Other Identifiers
ISSN
0012-6667
E-ISSN
1179-1950
DOI
10.2165/00003495-200969070-00006
